About Us

Mission & Values

Our mission is to transform the treatment paradigm for patients with inherited disorders by developing durable, broadly applicable, life-altering therapies grounded in innovative and rigorous science. By advancing a new category of genetic medicine, at SalioGen, we aspire to treat all inherited disorders, rare or common. At SalioGen, we bring together multidisciplinary group of scientists, drug developers, business leaders and key opinion leaders both from academia and the biotech industry with the breadth and depth of experience needed to bring new, innovative and transformative therapies to patients in need.

Leadership

Ray Tabibiazar

Ray Tabibiazar, M.D.

Chief Executive Officer
Chairman, Board of Directors

Joseph Higgins

Joseph J. Higgins, M.D.

President & Chief Scientific Officer
Board Member

Sung Yu

Sung You, M.S., MBA

Chief Business and Strategy Officer

Nancy Craig

Nancy L. Craig, Ph.D.

Senior Vice President of
Genetic Engineering and Mobile Elements, Chair, Scientific Advisory Board

Jeff Kopacz

Jeff Kopacz, M.S., J.D.

Senior Vice President of
Intellectual Property & Contracts

Sandeep Nema

Sandeep Nema, Ph.D.

Senior Vice President of
Technical Operations

Board of Directors

Ray Tabibiazar, M.D.

Chief Executive Officer | Chairman, Board of Directors

Joe J. Higgins, M.D.

President & Chief Scientific Officer | Board member

Craig D. Gordon, M.D.

Board Member

Sukumar Nagendran, M.D.

Board Member

Sean Stalfort

Board Member

Scientific Advisory Board

Nancy L. Craig, Ph.D. | Johns Hopkins University School of Medicine

Chair, Scientific Advisory Board

Beverly Davidson, Ph.D. | Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania

Ronald M. Krauss, M.D. | University of California, San Francisco School of Medicine

Ellis J. Neufeld, M.D., Ph.D. | St. Jude Children’s Research Hospital

Jesse B. Owens, Ph.D. | University of Hawaii John A. Burns School of Medicine

Thomas Quertermous, M.D. | Stanford University School of Medicine

Executive Advisory Board

Andrew Lo, Ph.D. | The Charles E. and Susan T. Harris Professor of Finance and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management, co-Founder of BridgeBio Pharma

John Maraganore, Ph.D. | Founding Chief Executive Officer (CEO) and director of Alnylam Pharmaceuticals

Mark McClellan, M.D., Ph.D. | The Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University, former commissioner of the U.S. Food and Drug Administration (FDA) and former administrator of the Centers for Medicare & Medicaid Services (CMS)

Advisors

Brian Hew, Ph.D. | University of Hawaii

Andrew Knudten, M.S., MBA | Jaguar Gene Therapy

Mark E. Pennesi, M.D., Ph.D. | Casey Eye Institute, Oregon Health & Science University

Renee Ryals, Ph.D. | Casey Eye Institute, Oregon Health & Science University

Gaurav Sahay, Ph.D. | Oregon State University

Troy Short | Jaguar Gene Therapy

Wayne Tschetter, Ph.D. | Casey Eye Institute, Oregon Health & Science University

Matthew Wilson, M.D., Ph.D. | Vanderbilt University

Jonathan Yen, Ph.D. | St. Jude Children’s Research Hospital

Collaborators

Frederick Dyda, Ph.D.

Jaguar Gene Therapy

Alison B. Hickman, Ph.D.

National Institutes of Health

Investors

General Inception
Superstring Capital
Yonjin Venture
SSI Accelerator